MarketsandMarkets Biogene Confex 2022

16th - 17th June 2022 | Double Tree by Hilton San Diego- Mission Valley
CONFERENCE SPEAKERS
Advisors
John Rossi
John Rossi
Director, Translational Sciences ,
Kite Pharma


John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.


 Julius Goepp
Julius Goepp
Founder, CEO,
Scaled Microbiomics


Julius Goepp is the founder and CEO of Scaled Microbiomics, LLC, a pre-clinical stage biotech company focused on passive immunotherapy in the microbiome. Dr. Goepp trained in Pediatrics and Emergency Medicine at Children’s Hospital, Boston, and in Pediatric Infectious Disease at Johns Hopkins, where he was active in the promotion of Oral Rehydration Therapy for childhood diarrheal disease. In 2017, he founded Scaled Microbiomics after recognizing the potential for microbiome modulation through the use of little-known avian antibodies, or IgY. Since that time, his energies have been devoted to exploring the characteristics of those antibodies and developing a drug discovery platform based on their use as selective immunomodulators of complex microbiome signaling pathways and event cascades. In addition to his work, Goepp is passionate about cooking, flying, and exploring the outdoors.


 Emily Stein
Emily Stein
CEO,
Primal Health Inc.


Ph.D. founded Primal Health, LLC in 2017 to focus on improving the dental health of both humans and animals by producing oral microbiome modulation products. She has spent 12 years developing SMMRT technology at Primal Therapies, Inc., which is focused on using metabolic influencers to re-engineer disease-causing bacterial biofilms into those that are health-promoting, to decrease inflammation and to improve outcomes. Prior to that, she spent 7 years as a research fellow at Stanford University in Rheumatology and Immunology focused on the neuro-endocrine-immune axis in autoimmune and chronic inflammatory diseases. She holds a Ph.D. in Microbiology from the University of California at Berkeley where she studied inter- and intra-cellular signaling pathways involved in stress response and community development in bacteria and received her B.S. in Microbiology and Immunology at the University of Iowa where she studied the interaction between M. tuberculosis and innate immune cells.


Yug Varma
Yug Varma
CEO,
Phi Therapeutics


Yug Varma, PhD, is the cofounder and CEO of Phi Therapeutics, a venture-backed microbiome company focused on skin disorders based in San Francisco. He has an extensive background in bio-organic chemistry, microbiology, synthetic biology, and microbiome research. Yug received

his scientific training at several distinguished academic institutions, including Johns Hopkins University (PhD) and University of California, San Francisco


 Nicole M. Scott
Nicole M. Scott
CEO and Founder,
Cybele Microbiome


Nicole is a domain expert in the microbiome and data science who has spent the last 6 years in startups doing everything from marketing, business strategy, IP, data analysis, and fundraising. She studied at the University of Michigan and University of Chicago with Dr. Jack Gilbert, and was the first employee at Dr. Rob Knight’s microbiome startup Biota. She is cited more than 2000 times, published in prestigious journals such as Science and Nature, and is the author of several book chapters and patents. She also serves as an advisor to several other life science and biotech startups.


Matt Davis
Matt Davis
Director, Molecular biology and Sequencing,
Gritstone Oncology, Inc.


Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.  


Miten Jain
Miten Jain
Assistant Research Scientist,
University of California Santa Cruz


Miten is an Assistant Research Scientist at the University of California Santa Cruz. He did his PhD in Biomolecular Engineering and Bioinformatics at UC Santa Cruz in the nanopore group. His prior work and research interests include developing biological methods and software for: 1) analyzing genomics data; 2) long read sequencing of DNA and RNA; 3) resolving homopolymers and base modifications; 4) the nanopore MinION and PromethION sequencing platforms; and 5) sequencing and analysis of different classes of RNA (mRNA, rRNA, tRNA, non-coding RNA). His long term interests include combining sequence and structure information from DNA (genomics), RNA (coding and non-coding), and proteins, to better understand genome organization and function.

 


Matteo D’Antonio
Matteo D’Antonio
Assistant Project Scientist,
Frazer Lab UC San Diego, La Jolla


Matteo D’Antonio is an assistant project scientist in Kelly Frazer’s lab at UCSD, where is main focus is identifying the molecular mechanisms underlying the associations between genetic variation and disease. He got his Bachelor’s degree in biomedical engineering at Politecnico di Milano in Italy and his Master’s in Bioinformatics at the Technical University of Denmark. After that, he obtained his PhD at the European Institute of Oncology, where he studied the evolution of protein interaction networks and cancer genes. He joined UCSD in 2013 where he transitioned from cancer genomics to human genetics.


Speakers
Carl Saab
Carl Saab
Professor of Neuroscience,
Brown University



Santhoshi Krishnan
Santhoshi Krishnan
Senior Research Student,
University of Michigan


Santhoshi N Krishnan is a 5th-year doctoral student in the Department of Electrical and Computer Engineering at Rice University. She also holds a joint position as a Visiting Research Scholar at the Department of Computational Medicine and Bioinformatics at the University of Michigan, working under Dr. Arvind Rao. Her research interests lie in leveraging machine learning and spatial statistical methods to develop robust frameworks that characterize the disease microenvironment, with a special focus on cancer biology. Through her projects, she has been able to establish strong collaborative research relationships with healthcare providers, statisticians, and epidemiologists, with the aim of developing solutions that are in tune with real-world problems.
She holds a master’s degree in Bioengineering from Rice University, where she worked on quantifying the difference in treatment models in nuclear medicine. When not working, she enjoys reading science fiction books, baking, and plans to visit and hike through all the national parks in the Midwest region during her stay there.


Joshua Campbell
Joshua Campbell
Professor,
Boston University School of Medicine


Joshua Campbell received his Ph.D. in Bioinformatics from Boston University. He performed his postdoctoral research at Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT where he worked with The Cancer Genome Atlas (TCGA) to identify novel mutational drivers of lung cancer. He is currently an assistant professor in the Department of Medicine at Boston University School of Medicine where he develops novel Bayesian approaches to analyze data from single-cell genomic technologies to analyze cellular heterogeneity in lung and prostate cancer.


Arun Devotta
Arun Devotta
Associate Research Scientist,
New York University


Mr. Arun Devotta is an Associate Research Scientist in the lab of Jean-Pierre Saint-Jeannet. Arun has a Masters in Biomedical Engineering from Polytechnic Institute of NYU. His research interests include developmental Biology, genetics and cell signaling. He is currently studying the signaling pathways regulating neural crest and cranial placode progenitors specification in Xenopus, two embryonic cell populations which form most of the craniofacial skeleton and sensory organs, respectively. When he is not in the lab, he’s probably enjoying an espresso in room 1007S.


 Brittany Rife
Brittany Rife
University of Florida,
Research Assistant Scientist


I am a Research Assistant Scientist at the University of Florida in the College of Medicine. My research interests revolve around molecular evolution and epidemiology of infectious diseases both within and among hosts, with a focus in phyloanatomy, sociovirology, and transmission cluster dynamics. The goal of my research is to identify relationships among genetic sequence data that can inform us as to the driving factors of pathogen evolution, interaction, and spread using state-of-the-art sequencing approaches and technology.


 Manoj Bhasin
Manoj Bhasin
Director, Bioinformatics and Systems Biology Shared Resource,
Winship Cancer Institute


Manoj Bhasin, PhD, MS, holds joint appointments as Acting Associate Professor in the Department of Pediatrics and in the Department of Biomedical Informatics at Emory University School of Medicine. Dr. Bhasin serves as Director of Genomics, Proteomics, Bioinformatics and Systems Biology and as Aflac Director of Single Cell Biology Program at Children's Healthcare of Atlanta. Prior to joining Emory, he was assistant professor of medicine at Harvard Medical School and co-director of Genomics, Proteomics, Bioinformatics and Systems Biology Center at Beth Israel Deaconess Medical Center.

Dr. Bhasin is a member of the Cancer Immunology research program at Winship Cancer Institute of Emory University.


Kelly A Frazer
Kelly A Frazer
Director, Institute for Genomic Medicine,
University of California, San Diego


Dr. Frazer is an internationally renowned leader in the field of genome biology and medicine. She is the director of UC San Diego Institute for Genomic Medicine and founding chief of the Division of Genome Information Sciences in the Department of Pediatrics at UC San Diego.


Maya Ivanjesku
Maya Ivanjesku
Chief Scientific Officer,
Dakota Biotech


Maya Ivanjesku M.S. is a creative visionary, CSO and a formulation scientist at Dakota Biotech -The Live Probiotic Skincare company. With over 25 years of experience in developing products for the beauty industry, Maya is a formulation expert. Her career path started at Estee Lauder Companies where she was formulating products for Estee Lauder, Clinique, Origins, Bobby Brown, Aveda, LaMer etc. With her passion for science and nature, Maya also ventured into Biotech, OTC and topical Rx and Medical Device formulation and developed topical prescription formulas for numerous pharmaceutical companies. The diversity of her career path in formulating products, overseeing manufacturing, R&D and holding executive positions in numerous industries from cosmetic to pharmaceutical and biotech product launches, has lead Maya into an entrepreneurial opportunity at Dakota Biotech where LaFloreÒ Probiotic Skincare product line was born. Maya’s passion for wellness, education and helping people heal – naturally, is the main driver in developing performance focused products.


Denise Kelly
Denise Kelly
Investment Advisor,
Seventure



Ross Youngs
Ross Youngs
CEO & Founder,
Biosortia Pharmaceuticals


Ross O. Youngs, Founder and CEO - Mr. Youngs has over 30 years of inventing products, technologies and processes for a variety of industries. Mr. Youngs holds over 75 patents worldwide and is driven to innovate by a focus on better, faster and less expensive. Recent major innovations have included an R&D 100 Award for collaboration on biopolymer technologies. In 2009, the Company was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology which helped lead to the development of Biosortia’s drug discovery platform. In 1998, Mr. Youngs was awarded the Ernst & Young Ohio Entrepreneur of the Year award and the U.S. Small Business Administration honored Mr. Youngs as their national “Business Person of the Year” in a presentation made by Vice President Al Gore. 


 Julie Schwedock
Julie Schwedock
Associate Director, Microbial Development Team,
Takeda Pharmaceuticals


PhD is Associate Director of the Microbial Development Team at Takeda Pharmaceuticals. She leads a cross-functional Pharmaceutical Sciences team for Live Bacterial Products (LBPs) focused on treating dysbiosis of the gut microbiome. She also heads a functional line group that works on process development for microbial expression systems as well as LPBs. Prior to that she was Associate Director of Analytical Development and QC at Vedanta Biosciences, also working with LBPs, where she developed analytics in an uncertain regulatory landscape for a product now in Ph2 clinical trials. She was the Director of Microbiology R&D at Rapid Micro Biosystems, Inc., a company whose mission is to develop rapid microbiological techniques for pharma and food microbiology. And she also worked at Genomic Profiling Systems, a company whose mission was to develop rapid diagnostics for infectious disease. She received her Ph.D. from Stanford University, and her B.S. from MIT.


Naveen Babbar
Naveen Babbar
Executive Director, Precision Medicine Leader,
Novartis


Naveen Babbar, Ph.D., is currently a Precision Medicine Leader at Novartis Oncology. Before joining Novartis in 2014, Naveen led product development teams at multiple diagnostic companies, including Genmark Diagnostics. Naveen holds a Doctorate from the University of Arizona and a Postdoctoral fellowships from Sidney Kimmel Cancer Center at Johns Hopkins.


Yisrael Katz
Yisrael Katz
Director of Clinical Applications,
Calviri Inc.


Dr. Katz is a board-certified internal medicine physician and director of clinical applications for Calviri, Inc. In this role, Dr. Katz has been instrumental in setting up early-phase clinical trials for FAST Vaccines (Frameshift Antigens for Specific Therapy), for multiple indications including pediatric brainstem tumors as well as adult head/neck and non-small cell lung cancers. Dr. Katz’s medical training was completed at Georgetown University Hospital; he continues to practice inpatient hospital medicine at the University of California – San Diego. He is also the founder of Clinical Strategy, LLC, and is a nationally-recognized clinical educator, having taught at over twenty US medical schools. Dr. Katz’s background in translational research includes previous work in biochemistry and neuroimaging, ongoing drug discovery work for neurodegenerative disease at the University of Pennsylvania, and oncology diagnostics and therapeutics at Calviri and the Biodesign Institute in Arizona. 


 Paul Kassner
Paul Kassner
Senior Vice President, Quantitative & Computational Biology ,
RAPT Therapeutics



John Rossi
John Rossi
Director, Translational Sciences ,
Kite Pharma


John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.


Partha Das
Partha Das
Medical Director, Oncology CDx and Biomarkers,
Amgen



Francie Barron
Francie Barron
Vice President, Innovation Partnerships,
Cardea Bio



Christos Patriotis
Christos Patriotis
Program Director, Breast and GYN Cancers, and Bioinformatics,
NCI, NIH



Zheng Feng
Zheng Feng
Head, Molecular Biomarkers & Genomics,
EMD Serono



 Hedieh Saffari
Hedieh Saffari
Biomarker Clinical Assay Lead, Manager,
Pfizer



Mike Baratta
Mike Baratta
Scientific Director, Translational Biomarker Research ,
Takeda


Mike Baratta currently serves as a Scientific Director for the Clinical Biomarker Innovation and Development group at Takeda Pharmaceuticals in Cambridge, MA. He received his B.A. from Loyola University of Chicago and a Masters Certificate in Applied Healthcare Project Management from Villanova University. Mike began his career as a member of the Global Drug Metabolism group at Pharmacia/G.D. Searle and transitioned to a Principal Scientist role with Pfizer after the closure of the merger. Prior to joining Takeda in 2013, he served as a Director on Nonclinical Development, Pharmacokinetics and Biometrics with Duck Flats Pharma. Mike is a member of several FNIH biomarker consortia, industry committees and serves as a standing member of the NIH/NSD-B grant application reviewer.  Mikes research focus is mass spectrometry focused analytical assay development and clinical validation of post translation biomarkers supporting patient characterization/stratification strategies. 

 


Matteo D’Antonio
Matteo D’Antonio
Assistant Project Scientist,
Frazer Lab UC San Diego, La Jolla


Matteo D’Antonio is an assistant project scientist in Kelly Frazer’s lab at UCSD, where is main focus is identifying the molecular mechanisms underlying the associations between genetic variation and disease. He got his Bachelor’s degree in biomedical engineering at Politecnico di Milano in Italy and his Master’s in Bioinformatics at the Technical University of Denmark. After that, he obtained his PhD at the European Institute of Oncology, where he studied the evolution of protein interaction networks and cancer genes. He joined UCSD in 2013 where he transitioned from cancer genomics to human genetics.


Miten Jain
Miten Jain
Assistant Research Scientist,
University of California Santa Cruz


Miten is an Assistant Research Scientist at the University of California Santa Cruz. He did his PhD in Biomolecular Engineering and Bioinformatics at UC Santa Cruz in the nanopore group. His prior work and research interests include developing biological methods and software for: 1) analyzing genomics data; 2) long read sequencing of DNA and RNA; 3) resolving homopolymers and base modifications; 4) the nanopore MinION and PromethION sequencing platforms; and 5) sequencing and analysis of different classes of RNA (mRNA, rRNA, tRNA, non-coding RNA). His long term interests include combining sequence and structure information from DNA (genomics), RNA (coding and non-coding), and proteins, to better understand genome organization and function.

 


Matt Davis
Matt Davis
Director, Molecular biology and Sequencing,
Gritstone Oncology, Inc.


Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.  


 Nicole M. Scott
Nicole M. Scott
CEO and Founder,
Cybele Microbiome


Nicole is a domain expert in the microbiome and data science who has spent the last 6 years in startups doing everything from marketing, business strategy, IP, data analysis, and fundraising. She studied at the University of Michigan and University of Chicago with Dr. Jack Gilbert, and was the first employee at Dr. Rob Knight’s microbiome startup Biota. She is cited more than 2000 times, published in prestigious journals such as Science and Nature, and is the author of several book chapters and patents. She also serves as an advisor to several other life science and biotech startups.


Yug Varma
Yug Varma
CEO,
Phi Therapeutics


Yug Varma, PhD, is the cofounder and CEO of Phi Therapeutics, a venture-backed microbiome company focused on skin disorders based in San Francisco. He has an extensive background in bio-organic chemistry, microbiology, synthetic biology, and microbiome research. Yug received

his scientific training at several distinguished academic institutions, including Johns Hopkins University (PhD) and University of California, San Francisco


 Emily Stein
Emily Stein
CEO,
Primal Health Inc.


Ph.D. founded Primal Health, LLC in 2017 to focus on improving the dental health of both humans and animals by producing oral microbiome modulation products. She has spent 12 years developing SMMRT technology at Primal Therapies, Inc., which is focused on using metabolic influencers to re-engineer disease-causing bacterial biofilms into those that are health-promoting, to decrease inflammation and to improve outcomes. Prior to that, she spent 7 years as a research fellow at Stanford University in Rheumatology and Immunology focused on the neuro-endocrine-immune axis in autoimmune and chronic inflammatory diseases. She holds a Ph.D. in Microbiology from the University of California at Berkeley where she studied inter- and intra-cellular signaling pathways involved in stress response and community development in bacteria and received her B.S. in Microbiology and Immunology at the University of Iowa where she studied the interaction between M. tuberculosis and innate immune cells.


 Julius Goepp
Julius Goepp
Founder, CEO,
Scaled Microbiomics


Julius Goepp is the founder and CEO of Scaled Microbiomics, LLC, a pre-clinical stage biotech company focused on passive immunotherapy in the microbiome. Dr. Goepp trained in Pediatrics and Emergency Medicine at Children’s Hospital, Boston, and in Pediatric Infectious Disease at Johns Hopkins, where he was active in the promotion of Oral Rehydration Therapy for childhood diarrheal disease. In 2017, he founded Scaled Microbiomics after recognizing the potential for microbiome modulation through the use of little-known avian antibodies, or IgY. Since that time, his energies have been devoted to exploring the characteristics of those antibodies and developing a drug discovery platform based on their use as selective immunomodulators of complex microbiome signaling pathways and event cascades. In addition to his work, Goepp is passionate about cooking, flying, and exploring the outdoors.